

## Product Update:

pegaspargase (Oncaspar<sup>®</sup>) 750U/mL solution for injection/infusion  
SMC No. (1197/16)

### Baxalta

07 October 2016

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

pegaspargase (Oncaspar<sup>®</sup>) is accepted for use within NHS Scotland.

**Indication under review:** as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.

Pegaspargase (Oncaspar<sup>®</sup>) has been used in NHS Scotland as an unlicensed medicine for the treatment of ALL in children and adults; it has now been granted a product license.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

This assessment is based on data submitted by the applicant company up to and including 15 August 2016.

**Chairman**  
**Scottish Medicines Consortium**